University of Rome Tor Vergata, U.O.C. of Dermatology, Viale Oxford 81, 00133, Rome, Italy.
Expert Opin Biol Ther. 2013 Sep;13(9):1325-34. doi: 10.1517/14712598.2013.820701.
Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases, and TNF-α (tumor necrosis factor) is a pro-inflammatory cytokine that plays a critical role in the pathogenesis of these conditions. Adalimumab is an anti-TNF-α drug widely used for the treatment of both psoriasis and PsA. Controlled clinical trials demonstrated that adalimumab is characterized by a high degree of clinical response. The aim of this review is to report the safety, efficacy, and recent findings in the treatment of psoriasis and PsA with adalimumab.
This article reviews the results of Phase II, III, controlled, and observational clinical studies on adalimumab in the treatment of psoriasis and PsA. A systematic search was conducted using the Pubmed Medline database for primary articles.
Treatment of psoriasis and PsA represents a therapeutic challenge for dermatologists and rheumatologists. The efficacy, tolerability, and safety profiles suggest adalimumab as a suitable anti-psoriatic drug in the long-term treatment of psoriasis and PsA. Management of long-term treatment, loss of efficacy, and comorbidities has been described.
银屑病和银屑病关节炎（PsA）是慢性免疫介导性疾病，TNF-α（肿瘤坏死因子）是一种促炎细胞因子，在这些疾病的发病机制中起着关键作用。阿达木单抗是一种广泛用于治疗银屑病和 PsA 的抗 TNF-α药物。对照临床试验表明，阿达木单抗具有高度的临床反应性。本综述旨在报告阿达木单抗治疗银屑病和 PsA 的安全性、疗效和最新发现。
本文综述了阿达木单抗治疗银屑病和 PsA 的 II 期、III 期、对照和观察性临床研究结果。使用 Pubmed Medline 数据库对主要文章进行了系统检索。
银屑病和 PsA 的治疗对皮肤科医生和风湿病学家来说是一个治疗挑战。疗效、耐受性和安全性特征表明阿达木单抗是一种适合长期治疗银屑病和 PsA 的抗银屑病药物。已经描述了长期治疗、疗效丧失和合并症的管理。
